Multiple Sclerosis
Pipeline by Development Stage
Drug Modality Breakdown
On Market (17)
Approved therapies currently available
Competitive Landscape
44 companies ranked by most advanced pipeline stage
+14 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 5,468 patients across 50 trials
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
Natalizumab and Chronic Inflammation
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
Effect of Fingolimod on Neurodegeneration
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
Long-term Follow-up of Fingolimod Phase II Study Patients
Resistance Training and Amino Pyridine in Multiple Sclerosis
Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Fingolimod -Response According to Coping - Evaluation
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis